1	Longitudinal profiles of plasma gelsolin, cytokines and antibody expression
2	predict COVID-19 severity and hospitalization outcomes
3	
4	Meshach Asare-Werehene <sup>1,2,4,5</sup> , Michaeline McGuinty <sup>3,4,7</sup> , Agatha Vranjkovic <sup>3,4,7</sup> , Yannick
5	Galipeau <sup>3</sup> , Juthaporn Cowan <sup>3,4,5,7</sup> , Bill Cameron <sup>3,4,5,7</sup> , Curtis L. Cooper <sup>3,4,7</sup> , Marc-André
6	Langlois <sup>3,5</sup> , Angela M. Crawley <sup>3,4,5,6,8,9</sup> , Benjamin K. Tsang <sup>1,2,5,6</sup>
7	
8	
9	Departments of <sup>1</sup> Obstetrics & Gynecology, <sup>2</sup> Cellular & Molecular Medicine, <sup>3</sup> Biochemistry,
10	Microbiology & Immunology, <sup>4</sup> Medicine and <sup>5</sup> Centre for Infection, Immunity & Inflammation,
11	University of Ottawa, Ottawa, Ontario, Canada, K1H 8L1
12	<sup>6</sup> Chronic Disease Program and <sup>7</sup> Clinical Epidemiology Program, Ottawa Hospital Research
13	Institute, Ottawa, Canada, Ottawa, Ontario, Canada K1H 8L6
14	<sup>8</sup> Department of Biology, Carleton University, Ottawa, Ontario, Canada.
15	<sup>9</sup> Coronavirus Variants Rapid Response Network–Biobank, Canada.
16	
17	
18	Correspondence: Dr. Benjamin K Tsang, Chronic Disease Program, Ottawa Hospital Research
19	Institute, The Ottawa Hospital (General Campus), 501 Smyth Road, Ottawa, Canada K1H 8L6;
20	Tel: 1-613-798-5555 ext 72926;       Email: <u>btsang@ohri.ca</u>
21	
22	Conflict of Interest statement:
23	The authors have declared that no conflict of interest exists.
24	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 25 Abstract

**Background:** Prognostic markers for COVID-19 disease outcome are currently lacking. Plasma gelsolin (pGSN) is an actin-binding protein and an innate immune marker involved in disease pathogenesis and viral infections. Here, we demonstrate the utility of pGSN as a prognostic marker for COVID-19 disease outcome; a test performance that is significantly improved when combined with cytokines and antibodies compared to other conventional markers such as CRP and ferritin.

Methods: Blood samples were longitudinally collected from hospitalized COVID-19 patients as well as COVID-19 negative controls and the levels of pGSN in µg/mL, cytokines and anti-SARS-CoV-2 spike protein antibodies assayed. Mean±SEM values were correlated with clinical parameters to develop a prognostic platform.

**Results:** pGSN levels were significantly reduced in COVID-19 patients compared to healthy individuals. Additionally, pGSN levels combined with plasma IL-6, IP-10 and M-CSF significantly distinguished COVID-19 patients from healthy individuals. While pGSN and antispike IgG titers together strongly predict COVID-19 severity and death, the combination of pGSN and IL-6 was a significant predictor of milder disease and favorable outcomes.

41 Conclusion: Taken together, these findings suggest that multi-parameter analysis of pGSN, 42 cytokines and antibodies could predict COVID-19 hospitalization outcomes with greater certainty 43 compared with conventional clinical laboratory markers such as CRP and ferritin. This research 44 will inform and improve clinical management and health system interventions in response to 45 SARS-CoV-2 infection.

46 Trial Registration: N/A

47

48 Funding: The Ottawa Hospital Department of Medicine - Special Pandemic Agile Research
49 Competition

## 50 Introduction:

COVID-19 is a respiratory infectious disease caused by SARS-CoV-2 (1-4). Currently, 51 >460 million people are infected worldwide and >6 million SARS-CoV-2-related deaths have 52 53 been recorded (World Health Organization) thus, requiring urgent health care interventions. SARS-CoV-2 suppresses the adaptive arm (B and T lymphocytes) of the immune system and 54 overly activates the innate arm (macrophages, natural killer cells, dendritic cells), causing an 55 inflammatory cytokine storm (TNF-a, IL-6, IL-8, IL-1β, MCP-1) (5). These immune reactions 56 57 can result in lung damage, multiple organ dysfunctions and in severe cases, death (5, 6). To date, 58 direct therapeutic options are limited to a modestly effective antiviral that remains inaccessible to most patients. Patients are managed using best supportive care including steroids, and in severe 59 cases the use of mechanical ventilation and extracorporeal membrane oxygenation (ECMO) (7, 8). 60 61 Identifying novel biomarkers will enable physicians to predict/assess the progress of COVID-19 62 patients and inform decision-making for available therapeutic intervention.

Lower viral titers contribute to false negative testing for SARS-CoV-2 (9, 10). Thus, an additional screening method that could detect possible infections despite lower viral titers will be highly beneficial. Antibodies directed to the nucleoprotein of SARS-COV-2 could be useful in identifying recent infections given most of the population will have detectable anti-spike antibody from prior infection and/or immunization (9, 10). As to whether their detection could be used to determine COVID-19 disease severity and clinical outcomes remain to be examined.

Laboratory markers including interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, platelets, lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), D-dimer and lymphopenia are significantly implicated in COVID-19 complications (11, 12). Diseases like influenza, bacterial infection, and chronic inflammatory and neurodegenerative diseases trigger the elevation of these laboratory markers (13-15), hence casting doubts on their specificity and sensitivity as reliable prognostic markers for COVID-19 severity, hospitalization outcomes and

75 ICU admissions.

76 Recently, proteomic screening of plasma samples from individuals with active COVID-19 disease has shown that plasma gelsolin (pGSN) expression levels are downregulated compared to 77 78 healthy controls (16-18). Gelsolin (GSN) is a 80-85kDa calcium-dependent multifunctional actinbinding protein which exists in three isoforms: cytoplasmic gelsolin (cGSN), pGSN, and gelsolin 79 3 (19, 20). pGSN has recently been shown to be a key player in the immune regulation of cancer 80 (21). pGSN depletion significantly reduces its organ-protective function, leading to multi-organ 81 dysfunction syndrome (MODS), increased mortality and long-term morbidity in survivors, 82 83 complications that are commonly seen in COVID-19 patients (22-25).

Thus, it is conceivable that pGSN could be of clinical relevance in the pathogenesis of COVID-19. Its pathological significance and potential as a biomarker for COVID-19 severity and treatment response remains to be determined. In the present study, we have demonstrated a pGSN multi-analyte panel as a potential biomarker of poor COVID-19 outcomes and pGSN with cytokines and antibodies present as a significant predictor of COVID-19 hospitalization outcomes compared with conventional clinical laboratory markers.

90

# 91 **Results:**

pGSN's combination with IL-6, IP-10 and M-CSF significantly distinguish hospitalized 92 COVID-19 patients from healthy controls. COVID-19 negative and positive patients were 93 recruited at TOH and their blood longitudinally collected. The subjects were stratified into 94 COVID-19 negative and positive subjects and the levels of pGSN, cytokines and antibodies were 95 96 quantified (Fig. 1A). There were no significant differences in the levels of pGSN between males and females as well as age references (Suppl. Fig S1A and SB). pGSN levels were significantly 97 98 lower (p<0.0001) in COVID-19 patients compared with the negative subjects (Fig. 1B). On the 99 contrary, IL-6 (p=0.034), M-CSF (p=0.001) and IP-10 (p=0.023) levels were significantly up-

100 regulated in COVID-19 patients compared with the negative subjects whereas HGF and CTAK 101 demonstrated a tendency to be significantly higher (Fig. 1B). The ratio of pGSN and cytokines were calculated and used in several ratio analyses. The mean levels of pGSN/IL-6, pGSN/M-CSF, 102 103 pGSN/HGF, pGSN/IP-10 and pGSN/CTAK were determined and compared between COVID-19 patients and COVID-19 negative controls. All ratios tested were significantly decreased in 104 105 COVID-19 patients compared with COVID-19 negative controls (Fig. 1C; p < 0.0001). ROC 106 curves were used to determine the diagnostic significance of these ratios in differentiating 107 COVID-19+ patients from COVID-19- controls (Fig. 1D). The combination of pGSN with IL-6, IP-10 and M-CSF but not HGF provided a significant 100% test accuracy with AUC of 1 (Fig. 108 109 1D). Meanwhile, pGSN alone or cytokines alone provided a statistically significant AUC <1 (Fig. 1D). To determine if these markers predicted disease progression in COVID-19 patients, pGSN 110 111 levels measured over time were compared between days of sample collection. No significant 112 differences were observed over time between the groups; however, a significant improvement (p<0.002) in the levels of pGSN were observed on day 30, potentially suggesting patients' 113 conditions might be improving (Fig. 1E` and Suppl. Figs. S1C-G). 114

115

The combination of pGSN and IL-6, IP-10, HGF, CTAK and M-CSF is associated with 116 favorable COVID-19 outcomes. Having observed that pGSN significantly distinguishes 117 COVID-19+ patients from COVID-19 negative controls, its prediction of disease severity, 118 progression and hospitalization outcomes were subsequently investigated. Here, we correlated the 119 120 levels of pGSN at day 1 of hospitalization with the clinical outcomes of the patients prior to being discharged alive or death (Fig. 2). We observed that pGSN levels increased with increases in ICU 121 admissions (Fig. 2A). COVID-19 patients who were discharged had increased levels of pGSN 122 suggesting their recovery (Fig. 2A). Inflammatory cytokines (IL-6, IP-10, HGF, M-CSF and 123

124 CTAK) as well as pGSN were elevated in severe COVID-19 patients reminiscent of reported 125 cytokine storms (6, 26, 27) that are highly associated with increased organ damage (**Fig. 2B**).

Unlike cytokines, none of the antibody isotypes measured associated with disease 126 severity (Fig. 2B). In order to develop a stronger prognostic marker, pGSN was combined with 127 selected cytokines in a ratio to be compared between mild and severe cases, ICU admission and 128 hospitalization outcomes. pGSN/IL-6 was significantly higher in mild cases compared with 129 severe cases; pGSN/HGF and pGSN/IP-10 showed a similar trend although not significant (Fig. 130 2C). Meanwhile, pGSN/IgM was significantly higher in severe cases with pGSN/IgG (but not 131 pGSN/IgA) showing a similar trend (Fig. 2C). Although the ratio of pGSN and cytokines and IgA 132 had no significant association with intubation, pGSN/IgM and pGSN/IgG at day 1 were 133 significantly elevated in patients who were intubated during hospitalization (Fig. 2D). In terms of 134 ICU admissions, patients with significantly higher levels of pGSN/IL-6 and pGSN/HGF (but not 135 136 pGSN/IP-10, pGSN/IL-4 and pGSN/M-CSF) were admitted to the ICU (Fig 2E) with the antibodies having no significant impact. The levels of pGSN/IP-10, pGSN/CTAK, pGSN/IL-6 137 138 and pGSN/M-CSF (but not pGSN/HGF) were elevated in patients that were discharged (Fig. 2F), 139 suggesting that pGSN levels in combination with inflammatory cytokines especially pGSN/IL-6, may predict mild and favorable outcomes for hospitalized COVID-19 patients. 140

141

The pGSN/IL-6 ratio is a strong predictor of disease progression and outcomes relative to symptoms onset. To further strengthen the potential of using pGSN and cytokines as a multianalyte marker for COVID-19 outcomes, we investigated their utility in days from symptoms onset. Mild COVID-19 patients had significantly high pGSN/IL-6 amongst all the multi-analyte markers following day 4 of symptoms onset compared with moderate and severe COVID-19 patients, and pGSN/IP-10 and pGSN/HGF showed a trend toward this association (Fig. 3A;

**Suppl. Fig. S2A**). Patients admitted into the ICU as well as those who died had lower pGSN/IL-6, with pGSN/HGF showing a similar trend (**Fig. 2A; Suppl. Fig S2B-C**). Taken together, the pGSN/IL-6 ratio presents as a strong candidate which could be potentially used to monitor disease progression and hospitalization outcomes 4 days from symptom onset. Although pGSN levels correlated with SARS-COV-2 spike protein antibodies on day 8, their combination as a multianalyte marker did not provide a significant output for monitoring patient outcomes days from symptom onset (**Fig. 3B; Suppl. Figs. S2-S3**).

155

**pGSN levels are elevated in response to cytokine storm.** We have thus far demonstrated that 156 pGSN and inflammatory cytokines are elevated in severe COVID-19 disease although we have 157 158 yet to determine how they correlate with each other as well as that of the clinically used inflammatory markers. Here, we stratified patients into two groups based on their pGSN levels 159 160 (low and high) using an optimal cut-off point determined by Fisher's Exact Test. The mean 161 inflammatory cytokine levels (IL-6, IP-10, HGF, M-CSF and CTAK; Fig. 3C) and clinically used laboratory markers (INR, d-dimer, CRP, WBC, platelets, neutrophils; Fig. 3D) were 162 determined and compared between the groups. The mean levels of the cytokines (except CTAK) 163 164 were significantly higher in the high pGSN group compared with lower pGSN group (Fig. 3C) whereas only INR and CRP were elevated in the high pGSN group. These findings suggest that 165 pGSN could be upregulated as a feedback mechanism to fight the damage caused by the 166 167 inflammatory state of the patient.

168

pGSN/IgG and pGSN/IgM are strong predictors of worse COVID-19 outcomes. We further tested how reliable pGSN would be to monitor disease severity and hospitalization outcomes either alone or in combination with SARS-COV-2 spike antibodies at the time of hospitalization

172 (day 0). Using ROC curves, we derived AUC to assess the prognostic performances of these markers (Fig. 4). Using pGSN, CRP, IgG, IgM or IgA alone were not significantly predictive, 173 however the AUCs of pGSN/IgG and pGSN/IgM to predict severe COVID-19 were 0.893 174 175 (p=0.028) and 0.96 (p=0.01) respectively (Fig. 4A; Suppl. S4A). Similar outcomes were observed for pGSN/IgG (AUC=0.776; p=0.032) and pGSN/IgM (AUC=0.735; p=0.067) when 176 predicting COVID-19 death (Fig. 4B; Suppl. S4B). These findings suggest that pGSN/IgG and 177 pGSN/IgM could be potential markers for predicting disease severity and hospitalization 178 outcomes for COVID-19. 179

180

pGSN/IL-6 is a strong predictor of mild COVID-19 and favorable outcomes. Unlike the 181 182 antibodies, the inflammatory cytokines showed more promise when combined with pGSN for predicting mild and favorable COVID-19 outcomes (i.e. no-ICU admissions, and survival to 183 hospital discharge). pGSN, CRP and individual cytokines alone provided an AUC < 0.6 in 184 185 predicting mild COVID-19 disease (Fig. 5A; Suppl. Fig. S1C). Meanwhile, combining pGSN 186 with IL-6 (AUC=0.904; p=0.003) showed a more significant ability to predict mild COVID-19 and IP-10 (AUC=0.754; p=0.065), HGF (AUC=0.746; p=0.075) and TGF-\beta1 (AUC=0.765; 187 p=0.078) demonstrated a trend toward significance (Fig. 5A; Suppl. Fig. S4C). 188

Unlike the mild cases, there were no significant differences between the pGSN/cytokine panels and pGSN alone when predicting non-ICU admissions (**Fig. 5B; Suppl. Fig. S4D**). Interestingly, pGSN/CTAK (AUC=0.833; p=0.016), pGSN/M-CSF (AUC=0.772; p=0.049) and pGSN/SCGF-b (AUC=0.772; p=0.049) but not the other ratios, significantly predicted survival to hospital discharge of COVID-19 patients (**Fig. 5C**). As expected, a modest AUC (less than 6) was observed with pGSN, cytokines or clinical inflammatory markers alone, suggesting the need for a multi-analyte marker for disease monitoring in COVID-19 (**Fig. 5C; Suppl. Fig. S4E**).

196

Multi-analyte panel of pGSN with cytokines and antibodies predict more than one clinical 197 outcome of COVID-19. Using heat maps, we demonstrated how our multi-analyte panels could 198 199 enable us to predict two clinical outcomes at the same time; an approach that will be significantly useful in triaging patients. We observed that COVID-19 patients with increased levels of 200 pGSN/IL-6, pGSN/HGF and pGSN/IgM compared with the other markers are more likely not to 201 progress to severe disease and will eventually be discharged alive (Fig. 6A; Suppl. Fig. S5A). 202 203 The situation with pGSN/IgG was different since it is more predictive of severe disease and death in this study (Fig. 6A). Additionally, patients with increased levels of pGSN/IL-6, pGSN/IP-10 204 205 and pGSN/IgM compared with the other markers were more likely not to be admitted to the ICU and to survive to hospital discharge (Fig. 6B; Suppl. Fig. S5B). When ICU and disease severity 206 were used in the heat map analysis, we observed that patients with increased pGSN/IL-6, 207 208 pGSN/IP-10 and pGSN/IgM are likely to present with mild cased and will eventually avoid ICU admission. These findings suggest that by combining pGSN with cytokines more than one clinical 209 210 outcome could be predicted in COVID-19 cases from the first day of hospital visit.

211

### 212 Discussion

Our study reveals for the first time the prognostic significance of pGSN when combined with cytokines and anti-SARS-CoV-2 antibodies in COVID-19 infection. Specifically, we have demonstrated that pGSN is significantly downregulated in COVID-19 patients and in combination with cytokines and anti-SARS-COV-2 antibodies can predict COVID-19 severity and hospitalization outcomes.

218 Although pGSN levels were lower at the time of admission, a return to normal range in the levels

219 were seen at day 30 which is associated with improved outcome (i.e. discharge) in patients with 220 COVID-19 infection. pGSN alone outperformed cytokines (IL-6, IP-10, HGF and M-CSF) in discriminating COVID-19+ patients from non-COVID-19 suggesting that pGSN is a potential 221 222 biomarker indicative of COVID-19 infection. As shown in previous studies (5, 6, 28, 29), COVID-19 is characterized by the upregulation of pro-inflammatory cytokines which was evident 223 in our study with the upregulation of IL-6, IP-10, M-CSF, HGF, CTAK and TGF-b1. It is 224 interesting to note that the test accuracy of pGSN was enhanced when combined with IL-6, IP-10, 225 226 HGF and C-MSF in a multi-analyte panel. During cytokine storm (5), multi-organ damage results 227 in the release of actin filaments in the blood which are cleared, in part, by pGSN (30, 31), a process that may result in the decrease of pGSN in COVID-19 patients also. This might further 228 229 explain why combining pGSN with the pro-inflammatory cytokines provided much greater 230 accuracy since these markers are both systemically related to disease progression.

231 Prediction of hospitalization outcomes is key to the effective management of COVID-19 cases as well as allocation of hospital resources. However, there are currently no biomarkers which 232 233 reliably predict COVID-19 severity, ICU admission and death. We have shown that a multi-234 analyte panel using pGSN and cytokines can predict favorable hospitalization outcomes. pGSN/IL-6 was the strongest predictive marker (amongst other cytokines) for mild COVID-19+ 235 cases, ICU admissions and patient discharge. pGSN is a negative regulator of IL-6 and other pro-236 237 inflammatory cytokines secreted by monocytes and macrophages (32). Hence, pGSN could be secreted as a response to cytokine storm to prevent multiple organ damage as well as actin 238 filament toxicity. This notion is consistent with the observation that pro-inflammatory cytokine 239 levels were elevated in COVID-19+ patients with high pGSN. It is therefore note-worthy that 240 combining pGSN and IL-6 provided robust test accuracy for favorable outcomes compared to 241 individual markers alone, an indication of disease progression in the participants. Additionally, 242 our findings are consistent with a previous study that has demonstrated the immunomodulatory 243

effectiveness of human recombinant (rhu)-pGSN in the treatment of a single severe COVID-19 case (33). There is an ongoing double-blinded proof-of-concept trial (NCT04358406) to further assess the efficacy and safety of rhu-pGSN in severe COVID-19.

Another key observation in this study was the relationship between pGSN levels and antibodies 247 (IgA, IgM and IgG) against SARS-CoV-2 spike protein. From day 1 of sample collection through 248 day 30 we observed a pattern where the inverse relationship between pGSN and the antibodies 249 increased. An indication that with improving clinical status, pGSN levels are restored while 250 antibody levels, especially IgG, began to decline. This is consistent with the observation that 251 antibody levels were lower in patients with severe COVID-19. Some patients were treated with 252 253 corticosteroids; which could impact antibody levels. Unlike the pro-inflammatory cytokines, combining pGSN with the anti-spike IgG and IgM were strong predictive markers for severe 254 COVID-19 and COVID-19-related death. Actin remodeling is a crucial step in B-cell activation 255 256 and B-cell receptor function (34, 35). Although pGSN is a key protein in actin binding and remodeling (20, 30), we have yet to investigate whether it is directly involved in COVID-19 257 258 humoral immunity. This could explain the relationship between pGSN and the antibodies as 259 observed in these COVID-19 patients. As to whether pGSN has a direct function on the production of SARS-COV-2 antibodies is yet to be investigated. 260

An additional major finding was the ability to utilize pGSN/IL-6 as well as other markers (cytokines, antibodies and clinical laboratory inflammatory markers) to predict more than one clinical outcome. Of note, we observed that COVID-19 patients with high pGSN/IL-6 and pGSN/IgM presented with mild disease did not require ICU admission and were more likely to be discharged. The opposite was noted with pGSN/IgG. In situations where there are limited resources, this could potentially provide clinicians and hospital administrators' prior knowledge in prioritizing their resources such as ICU beds in terms of delivering care to COVID-19 patients.

268 In summary, a multi-analyte panel of pGSN, cytokines and SARS-COV-2 antibodies, present as potential biomarkers predicting disease severity, ICU admissions and COVID-19-related death. 269 Despite these promising findings, there are limitations that need to be acknowledged. The sample 270 271 size of this study is relatively small due to the difficulty in sampling patients longitudinally in a hospital setting. Antibody kinetics (levels and isotype) during the early infection could be 272 influenced by time since infection. Also, the control samples consist of out-patient populations 273 that had no recorded history of respiratory infection during sample collection. Having control 274 275 samples from patients who are SARS-CoV-2 negative but positive for other respiratory diseases 276 will further strengthen the reliability of pGSN multi-analyte panels. In future studies, patient sample size will be increased while we investigate the prognostic significance of pGSN multi-277 analyte panel in SARS-CoV-2 variant patients, vaccinated patients as well as convalescent plasma. 278

279

#### 280 Materials and Methods:

281 Ethics statement:

This study was approved by the Ottawa Health Science Network Research Ethics Board (OH
SNREB; Protocol# 20200200-01H) and conducted in accordance with the appropriate guidelines.
Written informed consent was obtained from all subjects.

285

286 Patient characteristics and plasma samples:

Forty participants (unvaccinated) recruited at The Ottawa Hospital (TOH) from 2020 to 2021 were included in this study. Plasma samples were serially collected from 28 PCR-confirmed SARS-CoV-2-infected patients admitted to hospital at days 0, 4, 8, 12 and 30. Plasma samples had pre-determined laboratory markers such as C-reactive protein (CRP), ferritin, white blood cells (WBC), d-dimer, neutrophils, platelets and international normalized ratio (INR). Twelve samples 292 collected from healthy controls were negative for SARS-COV-2. Non-COVID-19 subjects had no reported illnesses at the time of sample collection. COVID-19 severity was defined as mild (no 293 supplemental oxygen), moderate [supplemental oxygen, not high flow or no flow listed, no 294 295 intubation/mechanical ventilation – ex. No Bi-level Positive Airway Pressure (BiPap) /intubation)] and severe (high flow oxygen and non-invasive or invasive mechanical ventilation - ex. Yes 296 BiPap/intubation). The range and median of follow-up period was 87 and 10 days respectively. 297 Other details of patient demographics and baseline characteristics are described in 298 Supplementary Table 1. Patients received interventional management including antiviral 299 300 therapies (lopinavir/ritonavir, ribavirin, hydroxychloroquine and remdesivir) and non-antiviral adjunctive therapies (convalescent plasma, steroids, immune-modulators, anticoagulation, and 301 302 antibiotics) in addition to appropriate supportive care.

303

### 304 pGSN ELISA:

pGSN concentrations were assayed in the study participants by sandwich ELISA (Aviscera Bioscience, Inc. CA), according to manufacturer's instructions. The detection antibody was raised against human plasma (soluble) gelsolin. Plasma samples were diluted in a sample buffer (1/1500; Aviscera Bioscience, Inc. CA) and all analyses done in triplicate. Optical densities (OD) were determined using a microtiter plate reader at 450 nm. The blank was subtracted from the triplicate readings for each standard and sample and concentrations reported in  $\mu$ g/mL.

311

312 Cytokine Assay:

313 The concentrations of pro- and anti-inflammatory cytokines in plasma were quantified using 314 multiplexing immunobead assays analyzed using the BioRad Luminex machine (Bio-Rad 315 Laboratories, Hercules, CA, USA). Transforming growth factor  $\beta$  (TFG- $\beta$ ) -1, -2 and -3 were

quantified using the TGF-Beta 1,2,3 Magnetic Bead Kit (Milliplex, Millipore SIGMA) while all
remaining cytokines were assayed using the 48-plex Bio-Plex Pro<sup>™</sup> Human Cytokine Screening
Panel (BioRad, Mississauga, ON, CANADA). Cytokine concentrations were reported in pg/mL.

319

320 Anti-spike protein antibody assay:

A manual colorimetric ELISA was used to measure antibodies targeting SARS-CoV-2 spike 321 protein, a complete description of the methods can be found here (36). Briefly, high protein-322 binding Immulon 4 HBX clear 96-well plates (VWR International, Mississauga, ON, Canada, 323 #62402-959) were coated with 50 µL of 2 µg/mL full length trimeric Spike protein (NRC) diluted 324 in PBS and kept at 4°C on a shaker. After an overnight incubation, the plates were washed three 325 times with 200uL of PBST and blocked with 200 µL of 3% w/v skim milk powder in PBST for 1 326 327 hour at room temperature on a shaker. During that time, plasma samples were diluted in 1% w/vskim milk powder. The plates were washed again and 100uL of diluted plasma samples was added 328 to the plate. Additionally, positive and negative serum controls alongside an isotype-antigen 329 specific calibration curve (CR3022 Human IgG1 (Absolute Antibody, Ab01680-10.0), anti-SARS-330 CoV-2 S CR3022 Human IgA (Absolute Antibody, Ab01680-16.0), or anti-SARS-CoV-2 S 331 CR3022 Human IgM (Absolute Antibody, Ab01680-15.0)) was added to the plate and incubated 332 for 2h with shaking. The plates were washed again and 50uL of isotype specific secondary 333 antibodies (anti-human IgG#5-HRP (NRC), anti-human IgA-HRP (Jackson ImmunoResearch 334 335 Labs, 109-035-011), and anti-human IgM-HRP (Jackson ImmunoResearch Labs, 109-035-129) 336 added and incubated with shaking for 1 hour. The plates were then washed for one last time and developed using 100 µL of SIGMAFAST OPD Tablets (Sigma-Aldrich, P9187) dissolved in 20 337 338 mL of Water for Injection for Cell Culture (Thermo Fisher Scientific, A1287301). The reaction was stopped with the addition of 50uL of 3M HCl and the absorbance was measured at 490 nm 339

using a PowerWave XS2 Plate Reader (BioTek Instruments). Absorbance reads were blank
 adjusted and correlated with the linear portion of the calibration curve, hereby taking into account
 plate-to-plate variability and dilution factor. Concentrations of antibodies were reported in ng/mL.

343

344 Biostatistical methods:

The GraphPad Prism 8 (San Diego, CA, USA) and SPSS software version 28 (SPSS Inc., Chicago, 345 IL, USA) were used to perform all statistical analyses and two-sided  $P \le 0.05$  considered to 346 indicate statistical significance. Concentrations of pGSN in study groups were dichotomized by 347 their median cut-offs into low or high concentrations and correlated to clinicopathological 348 parameters (37) [age, sex, disease severity, inflammatory cytokines, IgG, IgA and IgM levels], 349 using Pearson's correlation test (two-tailed), Fisher exact test, Students' t test and Kruskal Wallis 350 351 test, as appropriate. Receiving operating characteristic (ROC) curves were used to assess the performance of pGSN, cytokines and multi-analyte panels over their entire range of values. The 352 area under the curve (AUC) was used as an index of global test performance to predict disease 353 354 severity. Heat maps were used to demonstrate the relationships between multi-analyte panels and clinical outcomes. 355

356

Author Contributions: M.A-W. and B.K.T. conceived and designed the study in partnership with A.M.C. Plasma samples were collected by B.C., C.L.C. and M.M and processed by A.V., and A.M.C. Clinical information was collected and curated by B.C., C.L.C., and M.M. pGSN analyses were performed by M.A-W and B.K.T. Cytokine assays were conducted by A.V. and A.M.C. while antibody measurements were completed by Y.G. and MA.L. M.A.W. analysed the data with scientific input from B.K.T., B.C., C.L.C., MA.L., M.M., J.C. and A.M.C. M.A.W. wrote the

363 paper with feedback from all authors.

# 364 Acknowledgements

- 365 This work was supported by a grant from The Ottawa Hospital Department of Medicine Special
- 366 Pandemic Agile Research Competition (M.M., C.L.C., J.C., A.M.C.).

- -

## 382 **References**

Li T. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2
 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital
 (V2.0). Emerg Microbes Infect. 2020;9(1):582-5.

Ng OT, Marimuthu K, Chia PY, Koh V, Chiew CJ, De Wang L, et al. SARS-CoV-2 Infection
 among Travelers Returning from Wuhan, China. The New England journal of medicine.
 2020;382(15):1476-8.

Ozma MA, Maroufi P, Khodadadi E, Kose S, Esposito I, Ganbarov K, et al. Clinical manifestation,
 diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Infez Med.
 2020;28(2):153-65.

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019
 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3).

3945.Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on395immune responses. Cell death and differentiation. 27. England2020. p. 1451-4.

6. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of proinflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2).

399 7. Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies
 400 between promising and disappointing results. Infez Med. 2020;28(2):198-211.

401 8. Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. A Review of SARS-CoV-2 and the 402 Ongoing Clinical Trials. International journal of molecular sciences. 2020;21(7).

403 9. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response to
404 Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;71(15):778-85.

40510.Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-Specific406Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020;52(6):971-7.e3.

407 11. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized
408 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.

409 12. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19
410 disease progression. Critical reviews in clinical laboratory sciences. 2020;57(6):389-99.

411 13. Goldberg I, Shalmon D, Shteinvil R, Berliner S, Paran Y, Zeltser D, et al. A second C-reactive
412 protein (CRP) test to detect inflammatory burst in patients with acute bacterial infections presenting
413 with a first relatively low CRP. Medicine. 2020;99(42):e22551.

414 14. Luan YY, Yao YM. The Clinical Significance and Potential Role of C-Reactive Protein in Chronic
415 Inflammatory and Neurodegenerative Diseases. Front Immunol. 2018;9:1302.

416 15. Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel
417 swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis. 2010;201(3):346418 53.

419 16. Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, et al. Ultra-High-

Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. Cell systems. 2020;11(1):1124.e4.

D'Alessandro A, Thomas T, Dzieciatkowska M, Hill RC, Francis RO, Hudson KE, et al. Serum
Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6
Level. Journal of proteome research. 2020.

425 18. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et al. Large-scale
426 Multi-omic Analysis of COVID-19 Severity. medRxiv : the preprint server for health sciences. 2020.

427 19. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. Plasma and cytoplasmic
428 gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature.
429 1986;323(6087):455-8.

430 20. Sun HQ, Yamamoto M, Mejillano M, Yin HL. Gelsolin, a multifunctional actin regulatory protein.
431 The Journal of biological chemistry. 1999;274(47):33179-82.

432 21. Asare-Werehene M, Communal L, Carmona E, Han Y, Song YS, Burger D, et al. Plasma Gelsolin
433 Inhibits CD8(+) T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in
434 Ovarian Cancer. Cancer research. 2020;80(18):3959-71.

Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, et al. Recombinant
plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol
(1985). 2004;96(1):25-31.

Yang Z, Chiou TT, Stossel TP, Kobzik L. Plasma gelsolin improves lung host defense against
pneumonia by enhancing macrophage NOS3 function. Am J Physiol Lung Cell Mol Physiol.
2015;309(1):L11-6.

Yang Z, Bedugnis A, Levinson S, DiNubile M, Stossel T, Lu Q, et al. Delayed administration of
recombinant plasma gelsolin improves survival in a murine model of severe influenza. F1000Res.
2019;8:1860.

Yang Z, Bedugnis A, Levinson S, Dinubile M, Stossel T, Lu Q, et al. Delayed Administration of
Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and
Penicillin-Resistant Pneumococcal Pneumonia. J Infect Dis. 2019;220(9):1498-502.

Yang SS, Lipes J. Corticosteroids for critically ill COVID-19 patients with cytokine release
syndrome: a limited case series. Canadian journal of anaesthesia = Journal canadien d'anesthesie.
2020;67(10):1462-4.

450 27. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for 451 monocytes and macrophages. Nature reviews Immunology. 2020.

Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of
concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.
Nature medicine. 26. United States2020. p. 453-5.

Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte
responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine.
2020;55:102763.

458 30. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding

459 protein in clearing actin from the circulation. The Journal of clinical investigation. 1986;78(3):736-42.

460 31. Feldt J, Schicht M, Garreis F, Welss J, Schneider UW, Paulsen F. Structure, regulation and 461 related diseases of the actin-binding protein gelsolin. Expert reviews in molecular medicine. 2019;20:e7.

462 32. Cheng Y, Hu X, Liu C, Chen M, Wang J, Wang M, et al. Gelsolin Inhibits the Inflammatory 463 Process Induced by LPS. Cellular physiology and biochemistry : international journal of experimental 464 cellular physiology, biochemistry, and pharmacology. 2017;41(1):205-12.

465 33. Catteeuw JV, DiNubile MJ. Recombinant human plasma gelsolin (rhu-pGSN) in a patient 466 hospitalized with critical COVID-19 pneumonia. Clinical infection in practice. 2021;12:100088.

467 34. Liu C, Miller H, Orlowski G, Hang H, Upadhyaya A, Song W. Actin reorganization is required 468 for the formation of polarized B cell receptor signalosomes in response to both soluble and 469 membrane-associated antigens. Journal of immunology (Baltimore, Md : 1950). 2012;188(7):3237-46.

470 35. Song W, Liu C, Upadhyaya A. The pivotal position of the actin cytoskeleton in the initiation 471 and regulation of B cell receptor activation. Biochimica et biophysica acta. 2014;1838(2):569-78.

472 36. Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al. A scalable serology 473 solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clinical & 474 translational immunology. 2022;11(3):e1380.

475 37. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 476 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506.

477

478

479

480

481

482

483

484

485

### 487 Figures:



488

Figure 1. pGSN's combination with IL-6, IP-10 and M-CSF significantly discriminates COVID-489 19 positive patients from negative subjects. (A) 28 samples were serially collected from PCR-490 confirmed SARS-CoV-2-infected patients and 12 samples collected from non-COVID-19 controls. 491 Samples were analyzed for the levels of pGSN, cytokines and anti-SARS-COV-2 antibodies. The 492 mean levels of the analyte were compared between COVID-19 negative and positive subjects. 493 The test performances of the biomarkers against clinical outcomes were analyzed. (B) The 494 mean±SEM levels of pGSN, IL-6, IP-10, M-CSF, HGF and CTAK were detected and compared 495 between COVID-19 and non-COVID-19 patients. (C) The ratio of pGSN and cytokines were 496 calculated and used as multi-analyte diagnostic panels. The mean±SEM levels of pGSN/IL-6, 497

pGSN/M-CSF, pGSN/HGF, pGSN/IP-10 and pGSN/CTAK were determined and compared
between COVID-19 and non-COVID-19 subjects. (D) The test performances of pGSN, cytokines
(IL-6, IP-10, HGF, M-CSF) and multi-analyte panels (pGSN/HGF, pGSN/IL-6, pGSN/M-CSF
and pGSN/IP-10) in differentiating COVID-19 patients from non-COVID-19 subjects were
determined using receiving operating characteristic (ROC) curves. (E) pGSN levels in blood
collected on day 0 and 30 were compared. P-values were calculated by independent sample t-test.

504



Figure 2. The combination of pGSN and IL-6, IP-10, HGF, CTAK and M-CSF is associated with 506 507 favorable COVID-19 outcomes. (A) pGSN levels at day 0 were determined and the mean±SEM compared between patients based on ICU admittance and hospitalization outcome. (B) The 508 mean±SEM levels of pGSN, IL-6, IP-10, M-CSF, HGF, CTAK, IgA, IgM and IgG were detected 509 510 and compared between patients based on disease severity. The ratio of pGSN and cytokines were calculated and used as multi-analyte diagnostic panels. (C) The mean±SEM levels of pGSN/IL-6, 511 pGSN/HGF, pGSN/IP-10, pGSN/IgG, pGSN/IgM and pGSN/IgA were determined and compared 512 513 between mild and severe COVID-19 patients as well as (D) intubation status and (E) ICU admittance with pGSN/IL-4 included. (F) The mean±SEM levels of pGSN/IP-10, pGSN/IL-6, 514 515 pGSN/CTAK, pGSN/M-CSF and pGSN/HGF were compared between deceased and discharged patients. P-values were calculated by one-way ANOVA and independent sample t-test. 516



517

Figure 3. pGSN/IL-6 multi-analyte is a strong marker for monitoring disease severity and 518 outcomes days from symptoms onset. (A) pGSN/IL-6, pGSN/IP-10 and pGSN/HGF levels were 519 utilized to monitor disease severity, ICU admittance and discharge following day 1 from 520 symptoms onset. (B) pGSN and SARS-COV-2 antibodies (IgG, IgM and IgA) were assessed on 521 day 8 and correlated using Pearson's test. (C) Patients were stratified into low and high pGSN 522 groups using an optimal cut-off point. The mean±SEM levels of IL-6, HGF, IP-10, M-CSF and 523 CTAK were compared between the groups using scatter plot. (D) The mean±SEM levels of INR, 524 CRP, d-dimer, WBC, neutrophils and platelets were compared between the pGSN groups using 525 scatter plot. P-values were calculated by one-way ANOVA and independent sample t-test. 526

527



Figure 4. pGSN/IgG and pGSN/IgM are strong predictors of worst COVID-19 outcomes. ROC curves were used to assess the test performances of IgG, IgA, IgM, pGSN/IgG, pGSN/IgM and pGSN/IgA in predicting (A) disease severity and (B) death.



543

Figure 5. pGSN/IL-6 is a strong predictor of mild COVID-19 cases and favorable outcomes. ROC curves were used to assess the test performances of IL-6, IP-10, HGF, TGF- $\beta$ 1, M-CSF, CTAK, SCGF- $\beta$ , CRP, pGSN, pGSN/IP-10, pGSN/IL-6, pGSN/HGF, pGSN/TGF- $\beta$ , pGSN/M-CSF and pGSN/SCGF- $\beta$  in predicting (A) mild COVID-19 cases, (B) no-ICU admissions and (C) discharged patients.

549

550

551

552





Figure 6. Multi-analyte panel of pGSN with cytokines and antibodies predict more than one clinical outcome of COVID-19. pGSN/IL-6, pGSN/HGF, pGSN/IP-10, pGSN/IgM and pGSN/IgG were used in a heat map analyses to predict (A) disease severity and hospitalization outcomes, (B) ICU admissions and hospitalization outcomes and (C) disease severity and ICU admissions.